Article Text

PDF
Education
Microscopic examination of Gram-stained smears for anogenital gonorrhoea in men who have sex with men is cost-effective: evidence from a modelling study
  1. Jolijn M Zwart1,2,
  2. Marie-Josee J Mangen1,
  3. Menne Bartelsman3,
  4. Martijn S van Rooijen3,
  5. Henry J C de Vries3,4,5,
  6. Maria Xiridou1
  1. 1 Centre for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven, The Netherlands
  2. 2 ChipSoft, Amsterdam, The Netherlands
  3. 3 STI Outpatient Clinic, Public Health Service of Amsterdam, Amsterdam, The Netherlands
  4. 4 Department of Dermatology, Academic Medical Center (AMC), University of Amsterdam, Amsterdam, The Netherlands
  5. 5 Academic Medical Center (AMC), Amsterdam Infection and Immunity Institute (AI&II), University of Amsterdam, Amsterdam, The Netherlands
  1. Correspondence to Dr Marie-Josee J Mangen, Centre for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven 3720, The Netherlands; marie-josee.mangen{at}rivm.nl

Abstract

Objective To assess the cost-effectiveness of three testing strategies with or without light microscopic Gram-stained smear (GSS) evaluation for the detection of anogenital gonorrhoea among men who have sex with men (MSM) at the Amsterdam STI clinic using a healthcare payer perspective.

Methods Three testing strategies for MSM were compared: (1) GSS in symptomatic MSM only (currently practised strategy), (2) no GSS and (3) GSS in symptomatic and asymptomatic MSM. The three testing protocols include testing with nucleic acid amplification test to verify the GSS results in (1) and (3), or as the only test in (2). A transmission model was employed to calculate the influence of the testing strategies on the prevalence of anogenital gonorrhoea over 10 years. An economic model combined cost data on medical consultations, tests and treatment and utility data to estimate the number of epididymitis cases and quality-adjusted life years (QALY) associated with gonorrhoea. Incremental cost-effectiveness ratios (ICERs) for the testing scenarios were estimated. Uncertainty and sensitivity analyses were performed.

Results No GSS testing compared with GSS in symptomatic MSM only (current strategy) resulted in nine extra epididymitis cases (95% uncertainty interval (UI): 2–22), 72 QALYs lost (95% UI: 59–187) and €7300 additional costs (95% UI: −€185 000 (i.e.cost-saving) to €407 000) over 10 years. GSS testing in both symptomatic and asymptomatic MSM compared with GSS in symptomatic MSM only resulted in one prevented epididymitis case (95% UI: 0–2), 1.1 QALY gained (95% UI: 0.1–3.3), €148 000 additional costs (95% UI: €86 000 to–€217 000) and an ICER of €177 000 (95% UI: €67 000–to €705 000) per QALY gained over 10 years. The results were robust in sensitivity analyses.

Conclusions GSS for symptomatic MSM only is cost-effective compared with no GSS for MSM and with GSS for both symptomatic and asymptomatic MSM.

  • homosexuality
  • bacterial infection
  • neisseria gonorrhoea
  • economic analysis
  • testing
  • Sexually Transmitted Diseases
  • Male
  • Quality-Adjusted Life Years
  • Point-of-care testing

Statistics from Altmetric.com

Footnotes

  • JMZ and M-JJM contributed equally.

  • Handling editor Jackie A Cassell

  • Contributors M-JJM, MX and JMZ were responsible for the design of the study. MX designed the mathematical model. M-JJM and JMZ designed the economic model. MSvR and MB collected and interpreted the sexual behaviour data. JMZ, M-JJM and MX drafted the paper. M-JJM and MX supervised the overall study. All authors reviewed and approved the final article.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Patient consent Not required.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Data sharing statement All relevant data are within the paper. Further details are available from the corresponding author on reasonable request.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.